Kestra Medical Technologies (NASDAQ:KMTS) Insider Sells $384,000.00 in Stock

Kestra Medical Technologies, Ltd. (NASDAQ:KMTS) insider Brian Daniel Webster sold 15,000 shares of the firm’s stock in a transaction that occurred on Tuesday, February 17th. The stock was sold at an average price of $25.60, for a total transaction of $384,000.00. Following the sale, the insider directly owned 379,786 shares of the company’s stock, valued at $9,722,521.60. The trade was a 3.80% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link.

Brian Daniel Webster also recently made the following trade(s):

• On Thursday, January 15th, Brian Daniel Webster sold 15,000 shares of Kestra Medical Technologies stock. The shares were sold at an average price of $22.80, for a total transaction of $342,000.00.
• On Monday, December 29th, Brian Daniel Webster sold 15,000 shares of Kestra Medical Technologies stock. The shares were sold at an average price of $26.59, for a total transaction of $398,850.00.

Kestra Medical Technologies Stock Up 3.0%

KMTS stock traded up $0.77 during mid-day trading on Thursday, hitting $26.32. 271,607 shares of the company were exchanged, compared to its average volume of 262,527. The firm has a fifty day simple moving average of $25.62 and a 200 day simple moving average of $23.59. The company has a market capitalization of $1.54 billion and a PE ratio of -8.30. Kestra Medical Technologies, Ltd. has a twelve month low of $13.25 and a twelve month high of $30.00. The company has a current ratio of 5.47, a quick ratio of 5.47 and a debt-to-equity ratio of 0.26.

Institutional Trading of Kestra Medical Technologies

A number of institutional investors and hedge funds have recently made changes to their positions in KMTS. Price T Rowe Associates Inc. MD lifted its holdings in shares of Kestra Medical Technologies by 137.5% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 4,369,429 shares of the company’s stock worth $115,878,000 after purchasing an additional 2,529,851 shares during the last quarter. Eventide Asset Management LLC increased its position in Kestra Medical Technologies by 285.7% in the second quarter. Eventide Asset Management LLC now owns 1,060,557 shares of the company’s stock worth $17,584,000 after buying an additional 785,557 shares during the period. Franklin Resources Inc. lifted its stake in Kestra Medical Technologies by 180.8% in the fourth quarter. Franklin Resources Inc. now owns 951,008 shares of the company’s stock valued at $25,221,000 after buying an additional 612,343 shares during the last quarter. Millennium Management LLC acquired a new position in shares of Kestra Medical Technologies during the first quarter valued at $11,036,000. Finally, Brown Advisory Inc. grew its position in shares of Kestra Medical Technologies by 34.1% during the fourth quarter. Brown Advisory Inc. now owns 1,688,356 shares of the company’s stock worth $44,775,000 after acquiring an additional 428,996 shares during the last quarter.

Analysts Set New Price Targets

Several analysts have issued reports on the company. Weiss Ratings restated a “sell (d-)” rating on shares of Kestra Medical Technologies in a research note on Wednesday, December 24th. Wells Fargo & Company boosted their price target on Kestra Medical Technologies from $27.00 to $28.00 and gave the company an “overweight” rating in a report on Friday, December 12th. Stifel Nicolaus set a $30.00 price objective on Kestra Medical Technologies in a research note on Friday, December 12th. The Goldman Sachs Group set a $24.00 price objective on shares of Kestra Medical Technologies in a report on Friday, January 16th. Finally, BTIG Research initiated coverage on shares of Kestra Medical Technologies in a research note on Tuesday, November 18th. They set a “buy” rating and a $32.00 target price for the company. Six equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $29.00.

About Kestra Medical Technologies

We are a commercial-stage, wearable medical device and digital healthcare company focused on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intuitive, intelligent, and connected. We have developed and are commercializing our Cardiac Recovery System platform, a comprehensive and advanced system that integrates monitoring, therapeutic treatment, digital health, and patient support services into a single, unified solution. The cornerstone of our Cardiac Recovery System platform is the ASSURE WCD, a next generation wearable cardioverter defibrillator (“WCD”) used to protect patients at an elevated risk of sudden cardiac arrest (“SCA”), a major public health problem that accounts for approximately 50% of all cardiovascular deaths in the U.S.